Avacincaptad pegol

Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration.^[1] Avacincaptad pegol is a complement inhibitor.^[1]

Avacincaptad pegol

Clinical data
Trade names	Izervay
Other names	Zimura
License data	US DailyMed: Avacincaptad pegol
Routes of administration	Intravitreal
Drug class	Complement inhibitor
ATC code	S01XA32 (WHO)
Legal status
Legal status	US: ℞-only[1]
Identifiers
CAS Number	1613641-69-2
DrugBank	DB15165
UNII	TT0V5JLG5B
KEGG	D11748
Chemical and physical data
Formula	C395H453F21N142Na39O262P39
Molar mass	13885.245 g·mol−1

Avacincaptad pegol was approved for medical use in the United States in August 2023.^[2][3][4]

Medical uses

Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.^[5]

Society and culture

Avacincaptad pegol is the international nonproprietary name.^[6]